Trial Profile

Perforomist [formoterol] vs. foradil [formoterol] evaluated by inspiratory capacity and HRCT [high resolution computed tomography]

Status: Withdrawn prior to enrolment

Phase of Trial: Phase IV

Latest Information Update: 15 May 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Formoterol (Primary) ; Formoterol (Primary)
Indications Chronic obstructive pulmonary disease
Focus Therapeutic Use

Most Recent Events

24 Oct 2008 Data will be presented at the Annual International Scientific Assembely of the American College of Chest Physicians (CHEST), 2008, as reported in a media relaese from Dey.
24 Sep 2008 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
31 Mar 2008 New trial record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com